KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EPS (Basic) (2018 - 2025)

Castle Biosciences (CSTL) has disclosed EPS (Basic) for 8 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 120.0% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.83 through Dec 2025, down 225.76% year-over-year, with the annual reading at -$0.83 for FY2025, 225.76% down from the prior year.
  • EPS (Basic) hit -$0.07 in Q4 2025 for Castle Biosciences, down from -$0.02 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.35 in Q4 2024 to a low of -$1.1 in Q1 2023.
  • Historically, EPS (Basic) has averaged -$0.31 across 5 years, with a median of -$0.21 in 2021.
  • Biggest five-year swings in EPS (Basic): plummeted 1066.67% in 2023 and later skyrocketed 488.89% in 2024.
  • Year by year, EPS (Basic) stood at -$0.25 in 2021, then crashed by 216.0% to -$0.79 in 2022, then surged by 88.61% to -$0.09 in 2023, then surged by 488.89% to $0.35 in 2024, then crashed by 120.0% to -$0.07 in 2025.
  • Business Quant data shows EPS (Basic) for CSTL at -$0.07 in Q4 2025, -$0.02 in Q3 2025, and $0.16 in Q2 2025.